£1M topical formulation lab expansion investment for MedPharm

14 Feb 2018

Expansion will accommodate new scientists to service the increase in demand for the company's formulation development, performance testing and manufacturing services.

MedPharm has announced a laboratory expansion following an internal investment of £1 million to increase its laboratory footprint in the UK by 60%.

£1M topical formulation lab expansion investment for MedPharm

The expansion is to accommodate the new scientists needed to service the increase in demand for its formulation development, performance testing and manufacturing services. This increased capacity will allow MedPharm to extend its service offerings across these key areas of expertise.

The expanded facilities will house MedPharm’s two automated testing services, MedStat-HT and MedFlux-HT, which are designed to de-risk client’s development programs and shorten development timelines.

MedFlux-HTis an automated system of 32 flow-through diffusion cells for measuring the in vitro permeation and penetration of drugs into and through human skin (IVPT). It can also be set up with other tissues determined by the medicine’s target site (e.g., mucosal, buccal, etc). The use of MedFlux-HT has been important in the support of patent claims, substantiation of marketing claims for OTC products, new chemical entity development, and development of generic products.

MedStat-HT is an automated system of 24 vertical diffusion cells (VDC) more commonly known as ‘Franz’ or ‘static’ cells for measuring the in vitro release of drug from topical medicines across synthetic membranes (IVRT). Its key benefits are its ability to better characterise formulation drug release properties for potential patent claim support, formulation optimisation and comparison, and potential product quality and stability specifications, with a reduction in experimental time and variability.

“We are very pleased to announce this investment which reflects the trust an increasing number of clients are placing in our services,” commented Dr Andrew Muddle, MedPharm’s co-founder and Chief Executive Officer.

“Our focus on the development topical and transdermal medicines which can benefit developers of new chemical entities, generics or OTC products alike is attracting ever-increasing interest and this expansion will accommodate the demand for our services in the coming years”.

Read More

Related tags

Market News

Related news

New portable and ready-to-use upper respiratory drug delivery solution

New portable and ready-to-use upper respiratory drug delivery solution

11 Oct 2018

PureHale is valuable to pharmaceutical partners seeking a system that can carry a range of formulations and comes in various container sizes.

Read more 
CPhI Worldwide announces the winners  of the 15th Pharma Awards

CPhI Worldwide announces the winners of the 15th Pharma Awards

10 Oct 2018

17 winners chosen from over 250 entries, with Nanobiotix winning both ‘CEO‘ and ‘Pharma Company of the Year’ categories.

Read more 
CMOs to benefit from double digit approvals for ADCs in the next 3 years

CMOs to benefit from double digit approvals for ADCs in the next 3 years

9 Oct 2018

Therapeutic ADC market expected to reach $4 billion by 2023.

Read more 
Micro-Sphere increases capsule filling capacity

Micro-Sphere increases capsule filling capacity

8 Oct 2018

The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.

Read more 
Symbiosis secures FDA viral vector process approval

Symbiosis secures FDA viral vector process approval

5 Oct 2018

Strengthens the CDMO's position as a centre of excellence as part of the viral vector drug development supply chain.

Read more 
Three-way collaboration to advance gene therapy

Three-way collaboration to advance gene therapy

4 Oct 2018

Partnership aims to increase the robustness and reduce costs for the manufacturing of AAV vectors.

Read more 
New horizontal flow wrapping machine for hermetic packages

New horizontal flow wrapping machine for hermetic packages

3 Oct 2018

Greater product protection thanks to reliable sealing technologies.

Read more 
Movement on the market reflected at CPhI Worldwide 2018

Movement on the market reflected at CPhI Worldwide 2018

3 Oct 2018

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

Read more 
Niche CDMO confirms spray drying for highly potent drugs

Niche CDMO confirms spray drying for highly potent drugs

1 Oct 2018

Idifarma's GMP spray drying technology for highly potent drugs up to Category 4 OEL/OEB is now operational.

Read more 
Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

Custom scalable turnkey PODs for flexible continuous bioprocess and viral vector facility solutions

1 Oct 2018

The PODs ease verification, qualification and validation challenges, and their flexibility allows them to support multiple products.

Read more